Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Not Available].

H Chen1, S Hall, B Zheng

  • 1Immunology Unit, Research Division, Glaxo Wellcome Research and Development, Medicines Research Centre, Stevenage, England.

Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|March 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Precise Measurement of the Chromoelectric Dipole Moment of the Charm Quark.

Physical review letters·2026
Same author

Precise Measurement of Matter-Antimatter Asymmetry with Entangled Hyperon-Antihyperon Pairs.

Physical review letters·2026
Same author

Observation of Λ[over ¯]p→K^{+}π^{+}π^{-}π^{0} and Λ[over ¯]p→K^{+}π^{+}π^{-}2π^{0}.

Physical review letters·2026
Same author

First Measurement of the D_{s}^{+}→K^{0}μ^{+}ν_{μ} Decay.

Physical review letters·2026
Same author

[Construction of an index system for assessment of schistosomiasis transmission risk following natural disasters].

Zhongguo xue xi chong bing fang zhi za zhi = Chinese journal of schistosomiasis control·2026
Same author

Observation of the Electromagnetic Radiative Decays of the Λ(1520) and Λ(1690) to γΣ^{0}.

Physical review letters·2026
Same journal

Ustekinumab Biosimilars versus Reference Ustekinumab for Moderate-to-Severe Plaque Psoriasis: A Pre-switch Systematic Review and Meta-analysis.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Correction: Mirikizumab as Induction and Maintenance Therapy in Chinese Patients with Ulcerative Colitis: A Subpopulation Analysis of the Randomized, Global Phase 3 LUCENT-1 and LUCENT-2 Trials.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Gene Therapy Strategies for Uveal Melanoma: Adeno-associated Virus Delivery Challenges and Translational Opportunities.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Review of Quality Attributes and Analytical Methods Used for Comparative Analytical Assessment of Monoclonal Antibodies as Part of Successful Biosimilar Approvals in the United States and European Union.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Impact of Repeated Antigen Exposure on Humoral Tolerance: Antidrug Antibodies After Single-Dose Versus Multi-dose Adalimumab.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

An Overview and Trend Analysis of Biosimilar Approvals in China.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
See all related articles

Tucaresol, an orally active drug, enhances T cell responses by forming Schiff bases, activating key signaling pathways for potential therapeutic use in infections and cancer.

Area of Science:

  • Immunology
  • Pharmacology
  • Biochemistry

Background:

  • CD4+ T lymphocytes orchestrate immune responses via interactions with antigen-presenting cells (APCs).
  • APC-T cell interactions involve cognitive and costimulatory signals, with Schiff base formation implicated in T cell activation.
  • Small molecules forming Schiff bases can act as costimulatory agents.

Purpose of the Study:

  • To develop and test tucaresol, a xenobiotic substituted benzaldehyde, as an orally bioavailable immunopotentiatory drug.
  • To elucidate the mechanism of action of tucaresol in enhancing T cell responses.
  • To evaluate the therapeutic potential of tucaresol in preclinical models.

Main Methods:

  • Investigated Schiff base formation between tucaresol and T cell surface amines.

Related Experiment Videos

  • Assessed tucaresol's effects on CD4+ and CD8+ T cell responses in vivo.
  • Analyzed cytokine production profiles (T helper 1 bias).
  • Studied tucaresol's impact on ion transport (K+, Na+) and MAP kinase signaling pathways (MEK, ERK2).
  • Evaluated therapeutic activity in murine models of viral infection and tumor growth.

    • Main Results:

    • Tucaresol is orally bioavailable and systemically active, enhancing CD4+ and CD8+ T cell responses.
    • Tucaresol selectively promotes a T helper 1 cytokine profile.
    • Therapeutic activity observed in murine models of viral infection and tumor growth.
    • Mechanism involves Schiff base formation, activating clofilium-sensitive K+/Na+ transport and converging with TCR signaling at the MAP kinase level.

    Conclusions:

    • Tucaresol is the first orally active, mechanism-based immunopotentiatory drug for therapeutic testing.
    • Its mechanism involves Schiff base formation, leading to enhanced T cell activation and signaling.
    • Tucaresol shows promise for treating chronic viral infections and cancers, currently in clinical trials.